Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Concomitant therapy for multiple sclerosis.

William H Stuart1, Patrick Vermersch

  • 1Peachtree Neurological Clinic, 3200 Downwood Circle, Suite 550, Atlanta, Georgia 30327, USA. whstuart@aol.com

Neurology
|December 15, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis.

Frontiers in immunology·2026
Same author

Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial.

European journal of neurology·2026
Same author

Validation and psychometric properties of the Multiple Sclerosis Autonomy Score (MSAS) in a French cohort: The FOCAL-MS 2 study.

Multiple sclerosis and related disorders·2026
Same author

Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.

European journal of neurology·2026
Same author

A Qualitative Study of Lived Treatment Experiences and Preferences of Long-Term DMT Users with Relapsing-Remitting Multiple Sclerosis.

Neurology and therapy·2026
Same author

A clustering-based approach to characterize autonomy profiles among multiple sclerosis patients: an application of the Qluster method in the FOCAL-MS2 study.

Journal of patient-reported outcomes·2026

Interferon beta (IFNbeta) is a primary treatment for multiple sclerosis (MS). For MS patients experiencing disease progression on IFNbeta, additional therapies may be used to potentially enhance treatment effects and slow disease advancement.

Area of Science:

  • Neuroimmunology
  • Clinical Neurology

Background:

  • Interferon beta (IFNbeta) is a standard first-line therapy for multiple sclerosis (MS).
  • Disease management in MS often requires adjustments when patients experience breakthrough disease despite initial treatment.
  • The complex and multifactorial nature of MS supports the exploration of combination therapies.

Purpose of the Study:

  • To review reported concomitant therapies used in the long-term management of multiple sclerosis.
  • To explore the rationale and potential benefits of using additional agents alongside interferon beta in MS patients with breakthrough disease.

Main Methods:

  • Literature review of reported concomitant therapies in multiple sclerosis management.
  • Analysis of the scientific rationale for combining therapeutic agents in MS.

Related Experiment Videos

Main Results:

  • Concomitant therapies are frequently administered to MS patients experiencing breakthrough disease on interferon beta.
  • These agents may offer synergistic effects, potentially improving disease control.
  • The review consolidates information on various agents used in combination therapy for MS.

Conclusions:

  • Combination therapy is a recognized strategy for managing breakthrough disease in multiple sclerosis.
  • Concomitant agents hold potential for synergistic effects in slowing MS progression.
  • Further research may elucidate optimal combination strategies for diverse MS patient profiles.